← Leaderboards
Jennifer E. Golden
Clemson University
$8,647,439
Attributed
$12,601,188
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,601,188 · 6
By mechanism
U19$6,558,534 · 1
R01$4,691,719 · 2
R21$1,350,935 · 3
Top collaborators
- Kenneth A Christensen9 shared
- James Culvin Morris9 shared
- Karl A Werbovetz9 shared
- Colleen B Jonsson6 shared
- Donghoon Chung5 shared
- Zhuo Michael Wang2 shared
- Kylene Kehn-Hall1 shared
Most similar at Clemson University
Same institution · by research overlap
- James Culvin Morris$3,378,560
- Kenneth A Christensen$1,261,527
- Meredith T Morris$1,916,016
- Karl A Werbovetz$2,499,323
- Lesly A Temesvari$2,710,568
Others in their field
Top investigators on “Small Molecule”
- David Heimbrook · Leidos Biomedical Research, Inc.$251,072,489
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Peter C Adamson · National Childhood Cancer Foundation$143,645,434
- Mark S Klempner · Tufts Medical Center$128,021,180
- Stuart L Schreiber · Harvard University (Medical School)$79,067,419
- Edward A Dennis · University Of California, San Diego$73,030,813
Research focus
Small MoleculeLeadIn VitroSeriesMetabolicPathogenCellsValidationAnalogStructureIn VivoDosePermeabilityScreeningEncephalitisNonstructural ProteinToxic EffectCellular AssayPharmaceutical PreparationsAntiviral AgentsFutureDrug KineticsInsightPharmaceutical Chemistry
Grant awards (21)
Impact of BDGR-49 treatment on VEEV induced neurological sequelae$452,769
R21 · FY2025 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$518,827
R01 · FY2024 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$66,149
R01 · FY2024 · AI
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement$1,971,109
U19 · FY2023 · AI · contact PI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$524,577
R01 · FY2023 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$66,149
R01 · FY2023 · AI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$18,826
R01 · FY2023 · AI
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement$583,618
U19 · FY2022 · AI · contact PI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$497,486
R01 · FY2022 · AI
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement$1,865,824
U19 · FY2021 · AI · contact PI
Accelerated discovery of cell-active SARS-CoV-2 polymerase inhibitors via molecular dynamic guided screening and optimization$442,542
R21 · FY2021 · AI · contact PI
Development of a multiplexed assay in kinetoplastid parasites to identify probes for glycolysis$223,077
R01 · FY2021 · AI
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement$1,042,983
U19 · FY2020 · AI · contact PI
Medicinal Chemistry Optimization of Anti-Alphaviral Leads and Elucidation of Target and Off Target Engagement$1,095,000
U19 · FY2019 · AI · contact PI
Lead Optimization of ML336, a Potent VEEV Inhibitor$594,463
R01 · FY2019 · AI
Lead Optimization of ML336, a Potent VEEV Inhibitor$655,453
R01 · FY2018 · AI
Identification of kinetoplastid parasite glucose uptake and subcellular localization inhibitors as therapeutic leads$271,486
R21 · FY2018 · AI
Lead Optimization of ML336, a Potent VEEV Inhibitor$663,500
R01 · FY2017 · AI
Identification of kinetoplastid parasite glucose uptake and subcellular localization inhibitors as therapeutic leads$184,138
R21 · FY2017 · AI
Lead Optimization of ML336, a Potent VEEV Inhibitor$415,531
R01 · FY2016 · AI
Lead Optimization of ML336, a Potent VEEV Inhibitor$447,681
R01 · FY2015 · AI